ANTI-NEUTROPHILEN-ZYTOPLASMATISCHE ANTIKORPER (ANCA): INDIKATIONSBEREICH UND ERFAHRUNGEN MIT DIESEM NEUEN AUTOANTIKORPER

Translated title of the contribution: ANCA: Clinical associations and experience with a newly recognized autoantibody

R. Stupp*, R. W. Dubs, H. I. Joller-Jemelka, P. J. Grob

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Antineutrophil cytoplasmatic autoantibodies (ANCA) have been tested in this laboratory for more than two years with a 3-fold increase in tests and positive results. The initial association with Wegener's granulomatosis has since been extended to microscopic polyarteritis and rapidly progressive glomerulonephritis. We review the published data. ANCA are not simply another laboratory test but have become an important tool for diagnosis, treatment monitoring and prevention of relapses in many vasculitis syndromes including some forms of rapidly progressive glomerulonephritis. The ANCA-associated antigens have been identified as a serin-proteinase and myeloperoxidase. This provides insights into the pathogenesis of the ANCA-related diseases.

Translated title of the contributionANCA: Clinical associations and experience with a newly recognized autoantibody
Original languageGerman
Pages (from-to)1001-1007
Number of pages7
JournalSchweizerische Medizinische Wochenschrift
Volume121
Issue number27-28
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'ANCA: Clinical associations and experience with a newly recognized autoantibody'. Together they form a unique fingerprint.

Cite this